title: Detection of a minor amorphous phase in crystalline etoricoxib by dynamic mechanical analysis: comparison with Raman spectroscopy and modulated differential scanning calorimetry.
abstract: Detection and quantification of the amorphous phase of etoricoxib bulk drug substances, a selective cycloogenase-2 inhibitor used for the treatment of osteoarthritis, rheumatoid arthritis, and dental pain, was carried out using modulated differential scanning calorimetry (MDSC), dynamic mechanical analysis (DMA), and Raman spectroscopy. Detection of amorphous content in pharmaceutical powders by DMA is a special application of dynamic mechanical spectroscopy. DMA was found to be a sensitive technique, able to detect the presence of an amorphous phase in a crystalline phase at concentrations as low as 0.5%. The limit of detection (LOD) determined for DMA was 2.5%. In comparison, Raman spectroscopy and MDSC had LOD values of 2% and 5% amorphous, respectively.
authors.affiliation: Merck Canada, Pointe Claire-Dorval, Quebec, Canada H9R 4P8. sophie_clas@merck.com
authors.forename: Sophie-Dorothee
authors.initials: SD
authors.lastname: Clas
authors.forename: Karine
authors.initials: K
authors.lastname: Lalonde
authors.forename: Karine
authors.initials: K
authors.lastname: Khougaz
authors.forename: Chad R
authors.initials: CR
authors.lastname: Dalton
authors.forename: Rana
authors.initials: R
authors.lastname: Bilbeisi
mesh_terms: D002152:Calorimetry, Differential Scanning / Q000379:methods*; D003460:Crystallization; D052246:Cyclooxygenase 2 Inhibitors / Q000737:chemistry*; D000077613:Etoricoxib; D011725:Pyridines / Q000737:chemistry*; D013059:Spectrum Analysis, Raman / Q000379:methods*; D013450:Sulfones / Q000737:chemistry*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib